SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN)
Clinical trials for SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN) explained in plain language.
Never miss a new study
Get alerted when new SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN) trials appear
Sign up with your email to follow new studies for SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Pfizer's new cancer drug combo tested in tiny early trial
Disease control TerminatedThis early-stage study tested a new drug called PF-08046037, alone or with another drug (sasanlimab), in 8 people with advanced lung, pancreatic, melanoma, or head & neck cancers. The goal was to check safety and how the body handles the drugs. The trial was terminated early, so …
Matched conditions: SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN)
Phase: PHASE1 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug combo tested for Hard-to-Treat cancers
Disease control TerminatedThis early-phase trial tested an experimental drug called INCA00186, alone or with other immunotherapy drugs, in people with advanced solid tumors such as head and neck or gastrointestinal cancers. The study aimed to find safe doses and check for early signs of effectiveness. It …
Matched conditions: SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN)
Phase: PHASE1 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 26, 2026 12:43 UTC